FY2024 EPS Estimates for Neurogene Raised by Leerink Partnrs

Neurogene Inc. (NASDAQ:NGNE) – Stock analysts at Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for shares of Neurogene in a note issued to investors on Monday, November 4th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn ($4.40) per share for the year, up from their previous forecast of ($4.52). The consensus estimate for Neurogene’s current full-year earnings is ($4.47) per share. Leerink Partnrs also issued estimates for Neurogene’s Q4 2024 earnings at ($1.15) EPS, FY2025 earnings at ($4.55) EPS and FY2026 earnings at ($5.95) EPS.

Separately, HC Wainwright cut their price objective on Neurogene from $51.00 to $49.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $51.00.

Neurogene Price Performance

Shares of NASDAQ NGNE opened at $69.50 on Thursday. The business’s 50 day moving average is $44.81 and its two-hundred day moving average is $39.16. Neurogene has a 52-week low of $12.49 and a 52-week high of $73.59.

Neurogene (NASDAQ:NGNE) last announced its quarterly earnings results on Friday, August 9th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.07). The business had revenue of $0.93 million for the quarter.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in NGNE. Quest Partners LLC purchased a new stake in Neurogene during the 2nd quarter worth about $55,000. SG Americas Securities LLC acquired a new stake in shares of Neurogene during the 1st quarter worth about $120,000. Rhumbline Advisers purchased a new stake in Neurogene during the second quarter worth approximately $491,000. Avoro Capital Advisors LLC purchased a new position in Neurogene in the second quarter valued at approximately $802,000. Finally, Bank of New York Mellon Corp acquired a new stake in Neurogene during the second quarter worth approximately $1,107,000. Hedge funds and other institutional investors own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.